Oppenheimer lowered the firm’s price target on Boston Scientific (BSX) to $90 from $100 and keeps an Outperform rating on the shares. The firm cites the company’s Q1 results and Q2/FY26 guide for the price target cut.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target lowered to $77 from $97 at Needham
- Boston Scientific price target lowered to $71 from $109 at Canaccord
- Boston Scientific price target lowered to $85 from $90 at Truist
- Boston Scientific upgraded to Buy from Hold at Nephron Research
- Boston Scientific price target lowered to $78 from $86 at Baird